Patients treated with subcutaneous injection of recombinant IL-10 (2 μg/kg) had discontinuous exposure, with a peak concentration of more than 13 ng/mL and less than 1 ng/mL after 24 h [75, 92] . Despite this, both anti-inflammatory activity and immune activation had been observed in clinical trials, including the suppression of IL-1 and TNFα and the enhancement of lipopolysaccharide induced IFNγ and Granzyme [79] . 


Section:il-10 treatment results in th1 immunity and cd8 + t cell activation